Risk of Severe Toxicity According to Site of Recurrence in Patients Treated With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer
Diane C. Ling(UPMC Hillman Cancer Center), Dwight E. Heron(Bon Secours Mercy Health), Wai‐Ying Wendy Yau(Massachusetts General Hospital), Umamaheswar Duvvuri(City University of New York), D.A. Clump(UPMC Hillman Cancer Center), Jonas T. Johnson(University of Pittsburgh), Julie E. Bauman(George Washington University), Robert L. Ferris(University of Pittsburgh), Seungwon Kim(UPMC Hillman Cancer Center), John A. Vargo(West Virginia University), James Ohr(University of Pittsburgh), Barton F. Branstetter(University of Pittsburgh Medical Center)
Cited by 70
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590